Related Experiment Video
Updated: Mar 20, 2026

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
Published on: May 19, 2020
Barriers to treatment completion among drug-sensitive tuberculosis patients: evidence from Indonesia's tuberculosis
Mahalul Azam1, Latifa Hanan1, Muhammad Azinar1
1Department of Public Health, Faculty of Medicine, Universitas Negeri Semarang, Semarang, Indonesia.
Background:
This study aimed to estimate the prevalence of loss to follow-up (LTFU) among tuberculosis (TB) patients in Indonesia and to identify associated factors.
Methods:
This study analyzed data from the 2022 Tuberculosis Information System in Indonesia. A total of 71,665 drug-sensitive TB patients were included in the analysis. Age, sex, employment status, diagnosis type, human immunodeficiency virus (HIV) status, diabetes mellitus, TB type, mode of treatment, treatment standard, referral status, and type of residence. Categorical variables were analyzed using chi-square tests, followed by multivariable logistic regression to identify confounder-adjusted independent predictors of LTFU.
Results:
The prevalence of LTFU was 18.4%. A higher likelihood of LTFU was observed among older adults aged ≥65 years (adjusted-prevalence-odds-ratio [aPOR], 1.862), men (aPOR, 1.187), unemployed individuals (aPOR, 1.136), non-referred patients (aPOR, 1.547), patients with HIV (aPOR, 3.712), and those obtaining TB drugs out of pocket (aPOR, 4.998). The strongest predictor was receipt of non-standard treatment, which was associated with a markedly increased likelihood of LTFU (aPOR, 26.912). In contrast, rural residence demonstrated a protective association (aPOR, 0.610). All associations were statistically significant (p<0.001).
Conclusion:
This study highlights a substantial burden of LTFU among TB patients in Indonesia, with nearly one in five patients discontinuing treatment. Multiple sociodemographic and clinical factors-particularly non-standard treatment, non-referral status, and HIV co-infection-were strongly associated with LTFU, underscoring gaps in the TB care continuum. These findings emphasize the need for targeted, patient-centered interventions, strengthened referral pathways, improved communication, and enhanced care coordination to reduce LTFU in high-risk groups.
More Related Videos
09:57System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
10:04Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Drug Therapy
Antianxiety Medications